---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-034467"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:59:55.656746+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# DiaMedica Q3 net loss $8.6M; ReMEDy2 trial at 50% enrollment

## Summary
- Net loss $8.6M in Q3 2025, up from $6.3M a year ago; R&D expense $6.4M, up from $5.0M.
- Cash and short-term investments $55.3M as of Sept 30, 2025; funded into 2H 2027.
- ReMEDy2 Phase 2/3 AIS trial enrollment nearing 50% of 200-patient interim target.
- Preeclampsia IST Part 1a expansion cohort enrolling; Part 3 fetal growth restriction screening starting soon.
- Pre-IND meeting with FDA on DM199 for preeclampsia held; update after minutes received.

## SEC filing metadata
- accession: 0001437749-25-034467
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774925034467/0001437749-25-034467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774925034467/dmtp20251112_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-034467
- JSON: https://secwatch.observer/filing/0001437749-25-034467.json
- Plain text: https://secwatch.observer/filing/0001437749-25-034467.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.